Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Scedosporiosis in patients with acute leukemia: a retrospective multicenter report Caira M; Girmenia C; Valentini CG; Sanguinetti M; Bonini A; Rossi G; Fianchi L; Leone G; Pagano LHaematologica 2008[Jan]; 93 (1): 104-10We retrospectively analyzed 542 proven/probable mould infections registered, in the course of 2 studies, in 8,633 patients with acute leukemia, focusing on scedosporiosis. We aimed to define scedosporiosis incidence and mortality rate over a 15-year period. Only 5 cases of scedosporiosis were identified, all of them involving patients with acute myeloid leukemia (AML). We also reviewed all cases of Scedosporium spp. infections in acute leukemia reported to date in the international literature. The 52 cases analyzed confirmed that acute myeloid leukemia is the category with the highest risk of scedosporiosis. Clinical features of scedosporiosis were extremely variable and closely related to patient immune status. Infection disseminated to multiple sites in a very high percentage of patients and outcome was confirmed to be very poor. In our surveys all patients died, in spite of Amphotericin B compounds or voriconazole administration. Our review of literature found scedosporiosis attributable mortality rate (AMR) to be 77%. In conclusion, scedosporiosis, although extremely rare, represents a big problem for clinicians because of its aggressive clinical presentation and the lack of an effective therapy. New drugs with in vitro activity against Scedosporium spp (voriconazole, posaconazole) should be considered. However, their clinical activity should be more widely demonstrated.|Acute Disease[MESH]|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Amphotericin B/therapeutic use[MESH]|Anti-Bacterial Agents/therapeutic use[MESH]|Child[MESH]|Child, Preschool[MESH]|Humans[MESH]|Leukemia/*complications/*diagnosis/epidemiology/mortality[MESH]|Male[MESH]|Middle Aged[MESH]|Mycetoma/*complications/*diagnosis/epidemiology/mortality[MESH]|Pyrimidines/therapeutic use[MESH]|Retrospective Studies[MESH]|Scedosporium/*metabolism[MESH]|Triazoles/therapeutic use[MESH]|Voriconazole[MESH] |